Research Analysts Set Expectations for DMAC Q1 Earnings

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of DiaMedica Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst M. Caufield anticipates that the company will earn ($0.18) per share for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for DiaMedica Therapeutics' current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics' Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.46) EPS and FY2029 earnings at $0.06 EPS.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01).

DiaMedica Therapeutics Stock Down 7.7 %

NASDAQ DMAC traded down $0.38 during trading hours on Friday, hitting $4.57. 140,595 shares of the company were exchanged, compared to its average volume of 69,275. The firm has a market cap of $195.85 million, a price-to-earnings ratio of -8.16 and a beta of 1.52. The company has a 50 day moving average of $5.93 and a two-hundred day moving average of $5.14. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $6.82.

Remove Ads

Institutional Trading of DiaMedica Therapeutics

A number of large investors have recently made changes to their positions in the company. Paragon Associates & Paragon Associates II Joint Venture grew its holdings in DiaMedica Therapeutics by 6.7% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 514,784 shares of the company's stock worth $2,795,000 after acquiring an additional 32,170 shares in the last quarter. Susquehanna International Group LLP lifted its position in shares of DiaMedica Therapeutics by 269.5% during the 4th quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock worth $2,035,000 after purchasing an additional 273,395 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of DiaMedica Therapeutics by 29.6% during the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company's stock worth $1,286,000 after purchasing an additional 70,070 shares in the last quarter. Northern Trust Corp increased its holdings in DiaMedica Therapeutics by 49.8% in the fourth quarter. Northern Trust Corp now owns 180,192 shares of the company's stock valued at $978,000 after buying an additional 59,902 shares during the last quarter. Finally, LPL Financial LLC raised its stake in DiaMedica Therapeutics by 8.2% in the fourth quarter. LPL Financial LLC now owns 152,000 shares of the company's stock valued at $825,000 after buying an additional 11,500 shares in the last quarter. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.